Creative Planning Sells 950 Shares of Regeneron Pharmaceuticals Inc (REGN)

Share on StockTwits

Creative Planning lessened its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 21.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,528 shares of the biopharmaceutical company’s stock after selling 950 shares during the period. Creative Planning’s holdings in Regeneron Pharmaceuticals were worth $1,318,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the stock. Diversified Trust Co grew its position in Regeneron Pharmaceuticals by 0.8% in the 4th quarter. Diversified Trust Co now owns 3,630 shares of the biopharmaceutical company’s stock worth $1,356,000 after purchasing an additional 30 shares during the last quarter. Nordea Investment Management AB grew its position in Regeneron Pharmaceuticals by 1.5% in the 3rd quarter. Nordea Investment Management AB now owns 4,215 shares of the biopharmaceutical company’s stock worth $1,703,000 after purchasing an additional 64 shares during the last quarter. Rehmann Capital Advisory Group grew its position in Regeneron Pharmaceuticals by 1,700.0% in the 3rd quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 68 shares during the last quarter. Prentiss Smith & Co. Inc. grew its position in Regeneron Pharmaceuticals by 1.1% in the 4th quarter. Prentiss Smith & Co. Inc. now owns 6,951 shares of the biopharmaceutical company’s stock worth $2,596,000 after purchasing an additional 77 shares during the last quarter. Finally, Intercontinental Wealth Advisors LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $33,000. 67.11% of the stock is owned by institutional investors and hedge funds.

In related news, VP Christopher R. Fenimore sold 1,848 shares of the stock in a transaction that occurred on Thursday, December 20th. The shares were sold at an average price of $358.97, for a total transaction of $663,376.56. Following the completion of the sale, the vice president now directly owns 9,871 shares of the company’s stock, valued at $3,543,392.87. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Joseph L. Goldstein sold 1,791 shares of the stock in a transaction that occurred on Thursday, January 10th. The shares were sold at an average price of $410.00, for a total transaction of $734,310.00. Following the sale, the director now directly owns 14,114 shares of the company’s stock, valued at $5,786,740. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,645 shares of company stock valued at $1,399,980. Company insiders own 12.42% of the company’s stock.

Several research analysts have commented on REGN shares. TheStreet upgraded shares of Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, January 17th. Leerink Swann set a $483.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 7th. They noted that the move was a valuation call. Oppenheimer set a $440.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, December 2nd. Argus restated a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 13th. Finally, BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, October 19th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $408.82.

Shares of NASDAQ:REGN opened at $406.86 on Monday. The company has a market capitalization of $44.03 billion, a PE ratio of 20.55, a P/E/G ratio of 1.62 and a beta of 1.27. Regeneron Pharmaceuticals Inc has a twelve month low of $281.89 and a twelve month high of $431.32. The company has a quick ratio of 3.30, a current ratio of 2.67 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 earnings per share for the quarter, topping analysts’ consensus estimates of $5.10 by $1.74. The company had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.73 billion. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The business’s revenue for the quarter was up 21.9% compared to the same quarter last year. During the same period in the prior year, the business posted $5.23 EPS. Equities analysts forecast that Regeneron Pharmaceuticals Inc will post 19.36 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was first reported by Fairfield Current and is owned by of Fairfield Current. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.fairfieldcurrent.com/news/2019/02/11/creative-planning-sells-950-shares-of-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: How to Invest in an Index Fund

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply